TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRβ

Cancer Biology and Therapy

Volumn 5, Issue 3, 2006, Pages 323-330

  Zhong, Li ^a   Guo, Xiao Ning ^a   Zhang, Xiu Hua ^a   Sun, Qi Ming ^a   Tong, Lin Jiang ^a   Wu, Zhi Xing ^a   Luo, Xiao Ming ^a   Jiang, Hua Liang ^a   Nan, Fa Jun ^a   Zhang, Xiong Wen ^a   Lin, Li Ping ^a   Ding, Jian ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b NONE   (China)

Author keywords

Angiogenesis; PDGFR ; Tyrosine kinase; VEGFR2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PAXILLIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CELL DIFFERENTIATION; CELL FREE SYSTEM; CELL MIGRATION; CELL PROLIFERATION; CHORIOALLANTOIS; DOWNSTREAM PROCESSING; DRUG EFFECT; DRUG INHIBITION; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE SRC; PROTEIN PHOSPHORYLATION;

EID: 33646426434     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.3.2543     Document Type: Article

References (20)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
3. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995; 129:895-8.
4. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273:30336-43.
5. Underiner TL, Ruggeri B, Gingrich DE. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 2004; 11:731-45.
6. Zhong L, Guo XN, Zhang XH, Wu ZX, Luo XM, Jiang HL, Lin LP, Zhang XW, Ding J. Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening. Biochim Biophys Acta 2005; 1722:254-61.
7. Chen Y, Zhang YX, Li MH, Zhao WM, Shi YH, Miao ZH, Zhang XW, Lin LP, Ding J. Antiangiogenic activity of 11,11′-dideoxyverticillin, a natural product isolated from the fungus Shiraia bambusicola. Biochem Biophys Res Commun 2005; 329:1334-42.
8. Zhang YX, Chen Y, Guo XN, Zhang XW, Zhao WM, Zhong L, Zhou J, Xi Y, Lin LP, Ding, J. 11,11′-dideoxy-verticillin, a natural compound possessing growth factor receptor tyrosine kinases inhibitory effect with antitumor activity. Anticancer Drug 2005; 16:515-24.
9. Koyama S, Takagi H, Otani A, Suzuma K, Nishimura K, Honda Y. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. Br J Pharmacol 1999; 127:537-45.
10. Sheu JR, Fu CC, Tsai ML, Chung WJ. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res 1998; 18:4435-41.
11. Tan WF, Lin LP, Li MH, Zhang YX, Tong YG, Xiao D, Ding J. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol 2003; 459:255-62.
12. Ashton AW, Yokota R, John G, Zhao S, Suadicani SO, Spray DC, Ware JA. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A (2). J Biol Chem 1999; 274:35562-70.
13. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998; 111:3621-31.
14. Sun L, McMahon G. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Discov Today 2000; 5:344-53.
15. Anan K, Morisaki T, Katano M, Ikubo A, Kitsuki H, Uchiyama A, Kuroki S, Tanaka M, Torisu M. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 1996; 119:333-9.
16. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 1993; 143:1377-88.
17. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2:471-8.
18. Raymond E, Faivre S, Vera K. Final results of a phase I and pharmacokinetic study of SU1248, a novel multi-target tyrosine kinase inhibitor in patients with advanced cancers. Proc Am Soc Clin Oncol 2003; 22:Abstract 769.
19. Druker BJ, Sawyers CL, Kantarjian H. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-42.
20. Demetri GD, von Mehren M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-80.